US OptionsDetailed Quotes
AXSM250516P90000
- 2.25
- 0.000.00%
15min DelayClose Apr 29 16:00 ET
0.00High0.00Low
2.25Open2.25Pre Close0 Volume165 Open Interest90.00Strike Price0.00Turnover105.64%IV20.17%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry2.25Extrinsic Value100Contract SizeAmericanOptions Type-0.1565Delta0.0097Gamma48.85Leverage Ratio-0.1777Theta-0.0083Rho-7.64Eff Leverage0.0561Vega
Axsome Therapeutics Stock Discussion
Axsome's MDD Drug Trial Reveals Unexpected Win in Sleepiness Subgroup
Axsome Wins 16+ Years of Market Exclusivity for Sunosi in Patent Settlement
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Can This New Migraine Drug Replace CGRP Inhibitors? Trial Shows 48x Success Rate
Axsome Shatters Expectations: Record 89% Growth for Depression Drug Auvelity, Pipeline Milestones Accelerate
Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal
has options
nfa be careful
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...
No comment yet